We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+12.62%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$615M
AUM Growth
+$85.2M
Cap. Flow
+$34.9M
Cap. Flow %
5.67%
Top 10 Hldgs %
53.32%
Holding
366
New
100
Increased
78
Reduced
73
Closed
88

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$19.3M
2
ASND icon
Ascendis Pharma A/S
ASND
+$14.9M
3
ZURA icon
Zura Bio
ZURA
+$14.1M
4
AAM
AA Mission Acquisition Corp
AAM
+$10.1M
5
ZLAB icon
Zai Lab
ZLAB
+$9.65M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$25.2M
2
ROIV icon
Roivant Sciences
ROIV
+$12.8M
3
MRK icon
Merck
MRK
+$8.86M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$8.32M
5
QURE icon
uniQure
QURE
+$5.48M

Sector Composition

Rank Sector Weight
1 Healthcare 85.92%
2 Financials 3.35%
3 Communication Services 0.57%
4 Technology 0.47%
5 Utilities 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ITI
201
DELISTED
Iteris, Inc.
ITI
$71.4K 0.01%
+10,000
New +$59.7K
SAGE
202
CALL
DELISTED
Sage Therapeutics
SAGE
$68.6K 0.01%
+9,500
New +$87K
FDMT icon
203
4D Molecular Therapeutics
FDMT
$554M
$64.9K 0.01%
6,000
+4,000
+200% +$66.4K
CVS icon
204
CVS Health
CVS
$122B
$62.9K 0.01%
+1,000
New +$58.3K
PRTC
205
DELISTED
PureTech Health
PRTC
$61.8K 0.01%
3,000
+2,300
+329% +$50.3K
GRAL
206
GRAIL Inc
GRAL
$2.87B
$60.6K 0.01%
4,401
-17,000
-79% -$258K
WST icon
207
West Pharmaceutical
WST
$24.9B
$60K 0.01%
200
-690
-78% -$211K
GLRE icon
208
Greenlight Captial
GLRE
$509M
$59.9K 0.01%
4,385
-8,000
-65% -$107K
ARGX icon
209
argenx
ARGX
$55.1B
$59.6K 0.01%
+110
New +$55.6K
OGN icon
210
Organon & Co
OGN
$3.56B
$59.3K 0.01%
3,100
+600
+24% +$12.4K
TRIP icon
211
TripAdvisor
TRIP
$1.25B
$58K 0.01%
4,000
-18,000
-82% -$279K
AZN icon
212
AstraZeneca
AZN
$249B
$54.5K 0.01%
350
+300
+600% +$48.4K
AXSM icon
213
Axsome Therapeutics
AXSM
$10.8B
$53.9K 0.01%
600
+300
+100% +$26.2K
FULC icon
214
CALL
Fulcrum Therapeutics
FULC
$288M
$53.5K 0.01%
15,000
-5,000
-25% -$37.1K
TVRD
215
Tvardi Therapeutics
TVRD
$23.7M
$49.1K 0.01%
4,430
– –
LABD icon
216
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$59.4M
$49.1K 0.01%
+840
New +$51K
ETNB
217
DELISTED
89bio
ETNB
$48.5K 0.01%
6,560
+1,000
+18% +$8.41K
KYNB
218
Kyntra Bio
KYNB
$29.1M
$48.2K 0.01%
+4,827
New +$72.8K
JWN
219
DELISTED
Nordstrom
JWN
$45K 0.01%
+2,000
New +$44.4K
CELC icon
220
Celcuity
CELC
$4.42B
$44.7K 0.01%
3,000
+1,600
+114% +$26.4K
OVID icon
221
Ovid Therapeutics
OVID
$495M
$44.5K 0.01%
37,743
+18,553
+97% +$19.4K
ARDX icon
222
Ardelyx
ARDX
$1.01B
$44.1K 0.01%
6,400
-63,600
-91% -$375K
MIST icon
223
Milestone Pharmaceuticals
MIST
$149M
$42.5K 0.01%
27,931
-174,529
-86% -$254K
MREO
224
Mereo BioPharma
MREO
$48.1M
$41.1K 0.01%
10,000
-45,400
-82% -$188K
UCTT
225
Ultra Clean Holdings
UCTT
$3.86B
$39.9K 0.01%
1,000
– –
7 8
9
10 11

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return

ADAR1 Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, ADAR1 Capital Management held 366 positions worth $615M, up 16% from $530M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

ADAR1 Capital Management deployed $34.9M of net new capital in Q3 2024, opening 100 new positions and adding to 78 existing holdings. Its largest new stake was Zura Bio: 3,770,649 shares worth $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 80% a quarter earlier, followed by Financials and Communication Services.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $25.2M trimmed.

  • ADAR1 Capital Management's largest Q3 2024 buy was Zura Bio: 3,770,649 shares worth $15.3M.
  • ADAR1 Capital Management added most to Immunovant in Q3 2024, an estimated $19.3M increase.
  • ADAR1 Capital Management's biggest Q3 2024 reduction was Protagonist Therapeutics, cutting an estimated $25.2M.
  • ADAR1 Capital Management fully exited uniQure in Q3 2024, selling an estimated $5.48M.
  • ADAR1 Capital Management's ten largest holdings make up 53% of its $615M portfolio in Q3 2024.
  • ADAR1 Capital Management opened 100 new positions and closed 88 in Q3 2024.
  • ADAR1 Capital Management's portfolio value rose 16% quarter-over-quarter to $615M.

Based on ADAR1 Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.